AVITA Medical has appointed Board Chairman Cary Vance as Interim CEO following Jim Corbett's departure, while preliminary third-quarter revenue is expected to reach approximately $17 million.
AVITA Medical has successfully raised approximately A$23 million through a private placement, positioning the company to advance its therapeutic acute wound care portfolio and target free cash flow by 2026.